Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2002

Study Completion Date

February 28, 2006

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

gemcitabine

DRUG

Cisplatin

Trial Locations (4)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Barnaul

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Moscow

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saint Petersburg

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ufa

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00191841 - Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy | Biotech Hunter | Biotech Hunter